Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Sun Pharma Advanced Research Company Limited
This is a multicenter, open label, non-randomized, single-arm, extension safety study to evaluate the long-term safety of SPARC0913. Subjects who completed the prior evaluator-masked clinical non-inferiority Study participated in the current study.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Men and women aged ≥18 years
Willing to participate and giving written informed consent
Willing to commit to study medication-dosing, study visits and follow-up visits to complete evaluation
Eligible to receive Latanoprost once a daily as monotherapy for treatment of glaucoma
You may not be if
History of allergic hypersensitivity or poor tolerance to latanoprost
History of Substance abuse or addiction (alcohol drugs) in the past 3 years
History of chronic use of concomitant medications in neurologic or psychiatric illness that would affect assessment of safety and effectiveness of the study medication
Any abnormality preventing IOP measurement
Clareo Health | Evaluation of Safety of SPARC0913 in Open Angle Glaucoma or Ocular Hypertension
